However, it might take several weeks for people taking Strattera to notice its effects. It was not clear whether ATX had enhanced positive effects of the MPH during daytime hours, but no negative effects were reported. The benefits of ATX were obtained without the adverse effects that accompanied the trials of MPH-IR administered after school.
Strattera: ADHD Medication Resources
There is limited clinical trial experience with STRATTERA overdose. During postmarketing, there have been fatalities reported involving a mixed ingestion overdose of STRATTERA and at least one other drug. There have been no reports of death involving overdose of STRATTERA alone, including intentional overdoses at amounts up to 1400 mg. In some cases of overdose involving STRATTERA, seizures have been reported.
Common Strattera side effects
STRATTERA should be used as a part of a total treatment program for ADHD that may includecounseling or other therapies. Ethnic origin did not influence atomoxetine disposition (except that PMs are more common in Caucasians). Patients should be instructed to use caution when driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by atomoxetine. In the event of capsule content coming in contact with the eye, the affected eye should be flushed immediately with water, and medical advice obtained. Hands and any potentially contaminated surfaces should be washed as soon as possible.
Traumatic brain injury
If you’ve had an allergic reaction to Strattera or any of its ingredients, your doctor will likely not prescribe the medication. Ask them about other medications that may be better options for you. Be sure to talk with your doctor about your personal and family health history. They’ll help determine whether or not Strattera is right for you. If your doctor prescribes this drug, they’ll likely monitor you closely for changes in your behavior. If you have an eye condition called narrow-angle glaucoma, symptoms may be more likely to occur when your pupils are dilated.
It classifies prescription stimulants as Schedule II controlled substances because they have a high risk of misuse and dependence. Atomoxetine should not be taken while you are using certain other medicines. Before taking atomoxetine, tell your healthcare provider about any prescription or over-the-counter (OTC) medicines, vitamins/minerals, herbal products, and other supplements you are using. People with no history of any psychotic illness or mania may experience symptoms.
4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. EM subjects with end stage renal disease had higher systemic exposure to atomoxetine than healthy subjects (about a 65% increase), but there was no difference when exposure was corrected for mg/kg dose. STRATTERA can therefore be administered to ADHD patients with end stage renal disease or lesser degrees of renal insufficiency using the normal dosing regimen.
It’s important to tell your doctor if you have a liver problem before starting Strattera treatment. Doctors typically prescribe a lower dose of this medication for people with liver problems. Your doctor will check your liver function to determine the correct dose for you.
Some pharmacies offer labels that have large print, braille, or a code you scan with a smartphone to convert text to speech. If your local pharmacy doesn’t have these options, your doctor or pharmacist may be able to direct you to one that does. If your doctor has prescribed Strattera and you’re interested in using atomoxetine instead, talk with them. You’ll also need to check your insurance plan, as it may only cover one or the other. The actual price you’ll pay depends on your insurance plan, your location, and the pharmacy you use. If you drink alcohol and you have questions about consuming it during Strattera treatment, talk with your is strattera a stimulant doctor.
STRATTERA may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate see CONTRAINDICATIONS. Pulse and blood pressure should be measured at baseline, following STRATTERA dose increases, and periodically while on therapy to detect possible clinically important increases. No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day see Clinical Studies. STRATTERA is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome.
First Time Taking Adderall: A Comprehensive Guide for ADHD Patients
A slight delay in onset of incisor eruption was seen at 50 mg/kg. A slight increase in motor activity was seen on Day 15 (males at 10 and 50 mg/kg and females at 50 mg/kg) and on Day 30 (females at 50 mg/kg) but not on Day 60 of age. In short-term controlled studies (up to 9 weeks), STRATTERA-treated patients lost an average of 0.4 kg and gained an average of 0.9 cm, compared to a gain of 1.5 kg and 1.1 cm in the placebo-treated patients. In a fixed-dose controlled trial, 1.3%, 7.1%, 19.3%, and 29.1% of patients lost at least 3.5% of their body weight in the placebo, 0.5, 1.2, and 1.8 mg/kg/day dose groups. Sudden deaths, stroke, and myocardial infarction have been reported in adults taking atomoxetine at usual doses for ADHD. Consideration should be given to not treating adults with clinically significant cardiac abnormalities.
In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine. There are no adequate studies of Strattera in pregnant women and it is not known if Strattera is secreted in human breast milk. Tell your doctor if you are pregnant or plan to become pregnant or if you are breastfeeding before using Strattera.
In general, the weight and height gain of pediatric patients treated with STRATTERA lags behind that predicted by normative population data for about the first 9-12 months of treatment. Subsequently, weight gain rebounds and at about 3 years of treatment, patients treated with STRATTERA have gained 17.9 kg on average, 0.5 kg more than predicted by their baseline data. After about 12 months, gain in height stabilizes, and at 3 years, patients treated with STRATTERA have gained 19.4 cm on average, 0.4 cm less than predicted by their baseline data (see Figure 1 below). The total daily dose in children and adolescents should not exceed 1.4 mg/kg or 100 mg, whichever is less.
ADHD Download
Psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania can be caused by STRATTERA at usual doses. In vitro drug-displacement studies were conducted with atomoxetine and other highly-bound drugs at therapeutic concentrations. Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin. Similarly, these compounds did not affect the binding of atomoxetine to human albumin.
- Atomoxetine is well-absorbed after oral administration and is minimally affected by food.
- It’s thought to help ease certain ADHD symptoms by increasing the amount of norepinephrine in the brain.
- If you have an eye condition called narrow-angle glaucoma, symptoms may be more likely to occur when your pupils are dilated.
- The drug’s side effects should go away soon after your last dose.
- Do not share your Strattera prescription with anyone, even another person with ADHD.
However, stimulants are often considered first-line treatments for ADHD due to their rapid onset of action and high efficacy rates. The choice between Strattera and other medications often depends on individual factors, including medical history, comorbid conditions, and personal preferences. When considering Strattera as a treatment option, it’s helpful to understand how it compares to other ADHD medications. Strattera vs Wellbutrin, for example, is a common comparison, as both are non-stimulant options used in ADHD treatment. While Strattera is specifically approved for ADHD, Wellbutrin (bupropion) is primarily an antidepressant that has shown some efficacy in managing ADHD symptoms. These side effects are generally mild to moderate and often subside as the body adjusts to the medication.
Strattera may reduce ADHD symptoms by about 25% within less than one month. Call your child or teenager’s doctor right away if they have any of the above signs, especially if they are new, sudden, or severe. Your child or teenager may need to be closely watched for suicidal thoughts and actions or need a change in medicine.
A personalized approach to ADHD management, which may include medication, behavioral therapies, and lifestyle modifications, is often the most effective strategy. However, it’s important to acknowledge that not all experiences with Strattera are positive. Some users report minimal improvements in their ADHD symptoms or find the side effects challenging to manage. A common challenge reported by users is the extended time it takes to see benefits compared to stimulant medications. However, there are some important contraindications and potential drug interactions to be aware of. Strattera should not be used in combination with monoamine oxidase inhibitors (MAOIs) due to the risk of serious, potentially life-threatening reactions.
In that the recommended ATX dosing limit for George’s weight had been reached, a trial of Adderall-XR 5 mg qam was added to the ATX regimen. This improved George’s behaviour further and increased his ability to sustain attention in school, but it also caused increased difficulty in falling asleep. The ATX dose was then split so that George received 18 mg ATX with the morning dose of stimulant and 18 mg ATX at dinnertime. George has continued on this regimen for 3 months, with marked improvement at home and school and no adverse effects.
Strattera is also not a controlled substance, and many patients do not want a medication that is labeled a controlled substance. Stimulants can be addictive and habit-forming and may need to be avoided in someone with a history of substance use disorders. Let a healthcare provider know if you’re pregnant or planning to become pregnant before taking Strattera. A healthcare provider will most likely tell you not to take Strattera, for example, if you’re taking any monoamine oxidase inhibitors (MAOIs)—such as Marplan (isocarboxazid) or Nardil (phenelzine). Each item on the ADHDRS maps directly to one symptom criterion for ADHD in the DSM-IV. Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received STRATTERA.